Use of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ receptor blockers in context of COVID-19 outbreak: a retrospective analysis

• 作者: Bin Cao Chaolin Huang Chen Wang Fei Zhou Frederick G.Hayden Guohui Fan Hui Li Jiapei Yu Jiuyang Xu Ke Xie Lianhan Shang Lixue Huang Luning Yang Peter W.Horby Xiaoying Gu Yeming Wang Yi Zhang Yimin Wang Zhibo Liu Zhisheng Huang
• 来源期刊: 医学前沿
• 年，卷（期）: 2020,（5）
• 所属期刊栏目: Research Articles
• 页码范围: 601-612
• 页数: 12页
• 语种: 英文

摘要

The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin H receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate.We performed a single-center,retrospective analysis of hospitalized adult COVID-19 patients in Wuhan,China,who had definite clinical outcome (dead or discharged) by February 15,2020.Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes.The medical records from 702 patients were screened.Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication,40 patients were receiving ACEI/ARB as part of their regimen,and 61 patients were on anti-hypertensive medication other than ACEI/ARB.We observed no statistically significant differences in percentages of in-hospital mortality (28％ vs.34％,P =0.46),ICU admission (20％ vs.28％,P =0.37) or invasive mechanical ventilation (18％ vs.26％,P =0.31) between patients with or without ACEI/ARB treatment.Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes.Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19.Patients should continue previous anti-hypertensive therapy until further evidence is available.